Frozen melanoma tissues yield extracellular vesicles with preserved diagnostic and immunogenic properties

• by Daniele D´Arrigo, Kyong-Su Park, Cecilia Lässer, Georgios Panagiotis Sigalas, Emma Symonds, Ornella Urzí, Camilla Locatelli, Roger Olofsson Bagge, Jan Lötvall, Rossella Crescitelli

• May 21, 2026

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

• by Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker, Annalen Bleckmann, Farastuk Bozorgmehr, Manik Chatterjee, Stefanie Groepper, Mathias Haenel, Judith S. Hecker, Max-Felix Häring, Daniel Heudobler, Norbert Hilf, Martin Hofmann, Meike Hutt, Andrea Mayer-Mokler, Sarah Missel, Manuel Ruh, Heiko Schuster, Olga Veremchuk, Moritz Kleemiss, Stefan Knop, Simon Laban, Martin Sebastian, Silvia Spoerl, Cedrik Michael Britten, Carsten Reinhardt

• May 31, 2026

Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis

• by Karolina Zarańska, Grażyna Kamińska-Winciorek, Alexander Jorge Cortez, Grażyna Wąsik, Maksymilian Gajda

• May 6, 2026

Engineering CAR T Cells to Resist Tumor Immune Suppression

CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models

• March 9, 2026

• 2 min